EGFR and central nervous system cancer: It is essential to recognize that, beyond CDKN2A/B, an array of biomarkers exists that are instrumental in tumor classification and should be taken into account, i.e. EGFR amplification, 1p/19q codeletion, and etc. Importantly, interpreting glioma-related molecular markers, such as the co-deletion of the 1p and 19q chromosomal arms, requires a composite analysis.